These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20374002)

  • 1. Immunogenicity of avian H5N1 influenza virus recombinant vaccines in cats.
    Uhl EW; Harvey SB; Michel F; Perozo Y; Gabbard J; Tompkins SM; Hogan RJ
    Viral Immunol; 2010 Apr; 23(2):221-6. PubMed ID: 20374002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.
    Stittelaar KJ; Lacombe V; van Lavieren R; van Amerongen G; Simon J; Cozette V; Swayne DE; Poulet H; Osterhaus AD
    Vaccine; 2010 Jul; 28(31):4970-6. PubMed ID: 20566392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of H5 hemagglutinin vaccine antigen in common duckweed (Lemna minor) protects against H5N1 high pathogenicity avian influenza virus challenge in immunized chickens.
    Bertran K; Thomas C; Guo X; Bublot M; Pritchard N; Regan JT; Cox KM; Gasdaska JR; Dickey LF; Kapczynski DR; Swayne DE
    Vaccine; 2015 Jul; 33(30):3456-62. PubMed ID: 26067184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prime/boost vaccination with HA DNA and Pichia-produced HA protein elicits a strong humoral response in chickens against H5N1.
    Stachyra A; Pietrzak M; Macioła A; Protasiuk A; Olszewska M; Śmietanka K; Minta Z; Góra-Sochacka A; Kopera E; Sirko A
    Virus Res; 2017 Mar; 232():41-47. PubMed ID: 28159612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
    Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
    Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
    Gao W; Soloff AC; Lu X; Montecalvo A; Nguyen DC; Matsuoka Y; Robbins PD; Swayne DE; Donis RO; Katz JM; Barratt-Boyes SM; Gambotto A
    J Virol; 2006 Feb; 80(4):1959-64. PubMed ID: 16439551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus.
    Zhang S; Xiao L; Zhou H; Yu Z; Chen H; Guo A; Jin M
    J Virol Methods; 2008 Dec; 154(1-2):99-103. PubMed ID: 18812190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and immunogenicity of hemagglutinin from highly pathogenic avian influenza virus H5N1 expressed in Nicotiana benthamiana.
    Pua TL; Chan XY; Loh HS; Omar AR; Yusibov V; Musiychuk K; Hall AC; Coffin MV; Shoji Y; Chichester JA; Bi H; Streatfield SJ
    Hum Vaccin Immunother; 2017 Feb; 13(2):306-313. PubMed ID: 27929750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Construction and experimental immunity of recombinant replication-competent canine adenovirus type 2 expressing hemagglutinin gene of H5N1 subtype tiger influenza virus].
    Gao YW; Xia XZ; Wang LG; Liu D; Huang G
    Wei Sheng Wu Xue Bao; 2006 Apr; 46(2):297-300. PubMed ID: 16736595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus.
    Römer-Oberdörfer A; Veits J; Helferich D; Mettenleiter TC
    Vaccine; 2008 May; 26(19):2307-13. PubMed ID: 18395947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus.
    Biesova Z; Miller MA; Schneerson R; Shiloach J; Green KY; Robbins JB; Keith JM
    Vaccine; 2009 Oct; 27(44):6234-8. PubMed ID: 19686692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.